Insulin Pen With Half-Unit Dosing Now Available in U.S. For Children and Young Adults
January 8, 2003
NovoPen(R) Junior Is Designed For Easy, Accurate and Flexible Insulin Administration
PRINCETON, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Novo Nordisk today
announced the availability of NovoPen(R) Junior, an insulin delivery system
for children and adults that features half-unit dosing increments, which
allows insulin doses to be finely tuned for patient needs. Designed to make
insulin administration easy, accurate and flexible, NovoPen Junior is a line
extension of the company's NovoPen(R), the most widely used insulin pen in the
"NovoPen Junior fills an important need among children and young adults
because it allows half-unit dosing," said Harold Starkman, MD, at the
Pediatric Diabetes Center, Morristown Memorial Hospital, Morristown, NJ. He
explained that, because of their small body size, many children with diabetes
require only small amounts of insulin to maintain proper control -- with some
requiring very finely tuned doses. "NovoPen Junior allows people with
diabetes, particularly children and young adults, to administer insulin more
accurately to meet their needs," he said.
Dr. Starkman said that the incidence of diabetes is increasing
dramatically in children. "It's more important than ever before to make
insulin therapy as easy and as accurate as possible for those who need it," he
said. He added that the bright and colorful look of NovoPen Junior may
encourage children to more easily accept and incorporate a daily insulin
regimen into their lives.
NovoPen Junior is available in two fun colors, to help patients tell their
different insulin types apart. Insulin therapy is administered with NovoPen
Junior by dialing the dose, inserting the needle, and pushing the injection
button. The dosage dial is graduated in half-unit markings and can administer
from one to 35 units.
NovoPen Junior is designed for use with Novo Nordisk's range of PenFill(R)
3 mL cartridges, which contain 300 units of insulin. It is used with
NovoFine(R) disposable needles, including NovoFine 31-gauge (6 mm) needles,
whose design may help make insulin injections more comfortable.
NovoPen Junior is available as part of a complete diabetes management
system. The NovoPen(R) Junior Diabetes Management System includes: NovoPen
Junior, an interactive CD-ROM of games and activities that explain diabetes
and its treatment, an instructional video and brochure, a parent Q&A booklet,
NovoFine 31 disposable needles, and NovoPen(R)3 PenMate(R), an automatic
needle insertion device which hides the needle and is designed for quick, easy
injections. Shown to significantly reduce pain perception(1), NovoPen 3
PenMate was considered easy to use by 84% (N=57) of patients in a study(1).
The prevalence of diabetes is skyrocketing in many countries around the
world. In the United States, 17 million people, or 6.2 % of the population,
have diabetes, with an estimated 5.9 million sufferers unaware they have the
disease. Approximately 2,740 people are diagnosed with diabetes daily, and
nearly 1 million people will be diagnosed this year. Diabetes is the fifth
leading cause of death by disease in the United States.(2)
Among North American children and adolescents, the prevalence of type 2
diabetes has been rising at a dramatic rate. Prevalence has been estimated at
between 2 and 50 per 1000 in various populations, which represents as much as
a ten-fold increase over the past two decades.(3)
NovoPen, PenMate, PenFill, and NovoFine are registered trademarks of Novo
Nordisk A/S and are protected by U.S. patents and patents pending.
Always read the Instruction Manual for complete directions for use.
Novo Nordisk is a focused healthcare company and the world leader in
diabetes care. In addition, Novo Nordisk has a leading position within areas
such as hemostasis management, growth hormone therapy and hormone replacement
therapy. Novo Nordisk manufactures and markets pharmaceutical products and
services that make a significant difference to patients, the medical
profession and society.
With headquarters in Denmark, Novo Nordisk employs approximately 17,900
people in 68 countries and markets its products in 179 countries. For further
company information visit http://www.novonordisk.com.
(1) Diglas J, et al. Reduced pain perception with PenMate(R), an automatic
needle insertion device for use with an insulin pen. Data on file, Novo
Nordisk Pharmaceuticals, Inc.
(2) American Diabetes Association website, http://www.diabetes.org. Basic
Diabetes Information: Facts & Figures and National Diabetes Fact Sheet.
(3) Ludwig D and Ebbeling C. Type 2 diabetes mellitus in children:
Primary care and public health considerations. JAMA 2001; 1427-1430.
Be the first to comment on this article!